All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses
Further Supporting the Therapeutic Potential of HspE7
SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced positive immunological data from the third cohort of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. HPV 16 E7-specific T-cell responses were elicited in all four subjects in the study's third cohort following administration of 500 mcg of HspE7 and 1,000 mcg of Poly-ICLC, a potent toll-like receptor 3 (TLR-3) adjuvant. All T-cell responses represented significant changes from baseline, indicating that the responses were a direct result of treatment with HspE7. As previously announced, three out of four of the patients in cohort 2 (administered 500 mcg of HspE7 and 500 mcg of Poly-ICLC) demonstrated a T-cell response, which may validate that HspE7 is more active with an elevated dose of adjuvant.
"We continue to be very encouraged with the immunological results from our Phase 1 HspE7 trial as they demonstrate that administration of HspE7 induces T-cell responses that we believe to be therapeutic," said Gregory M. McKee, president and chief executive officer at Nventa. "These positive immunological data, along with the safety data analyzed to date, provide a strong foundation for our Phase 2 trial expected to begin mid-2008."
Independent research findings recently published in the journal
Gynecologic Oncology by Jeffrey Weber, M.D., Ph.D., associate director for
clinical research at the University of Southern California's Norris
Comprehensive Cancer Center, demonstrated that such an immune response may
be associated with objective c
|SOURCE Nventa Biopharmaceuticals Corporation|
Copyright©2008 PR Newswire.
All rights reserved